Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$120.28

-0.74 (-0.61%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

08:13
12/02/19
12/02
08:13
12/02/19
08:13

Seattle Genetics, Astellas Pharma announce trial collaboration with Merck

Seattle Genetics (SGEN) and Astellas Pharma (ALPMY) announced a clinical collaboration agreement with Merck (MRK), through a subsidiary, to evaluate the combination of Seattle Genetics' and Astellas' antibody-drug conjugate enfortumab vedotin and Merck's anti-PD-1 therapy, KEYTRUDA, in patients with previously untreated metastatic urothelial cancer. Under the terms of the agreement, the three companies will conduct and fund a global, registrational phase 3 clinical trial to be led by Seattle Genetics. The trial will be designed to evaluate the efficacy of the combination of enfortumab vedotin and pembrolizumab in patients with previously untreated locally advanced or metastatic urothelial cancer. The companies are working in consultation with regulatory authorities to finalize the trial design and currently plan to initiate the trial in the first half of 2020.

SGEN

Seattle Genetics

$120.28

-0.74 (-0.61%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

MRK

Merck

$87.10

-0.52 (-0.59%)

  • 04

    Dec

  • 07

    Dec

  • 10

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

  • 15

    Mar

SGEN Seattle Genetics
$120.28

-0.74 (-0.61%)

10/22/19
OPCO
10/22/19
NO CHANGE
Target $110
OPCO
Outperform
Seattle Genetics price target raised to $110 from $92 at Oppenheimer
Oppenheimer analyst Silvan Tuerkcan raised his price target for Seattle Genetics to $110 from $92 after tucatinib, the company's HER2+ targeting oral TKI, hit the primary endpoint of PFS improvement over control with a 46% reduction in the risk of disease progression or death. Tucatinib + trastuzumab + capecitabine also showed an improvement in OS with a 34% risk reduction and superior PFS in patients with brain metastases with a 52% risk reduction, he adds. The analyst views the early OS benefit as extremely positive as well as the brain metastasis outcome following his discussions with an expert at the MD Anderson brain metastasis clinic. Tuerkcan reiterates an Outperform rating on the shares.
10/22/19
RBCM
10/22/19
NO CHANGE
Target $109
RBCM
Outperform
Seattle Genetics price target raised to $109 from $80 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Seattle Genetics to $109 after the "unexpectedly impressive" phase 3 data of its tucatinib drug in patients with HER2-positive breast cancer. The analyst is boosting his breadth and depth forecasts for tucatinib across indications, also raising his market penetration estimates to 75% from 45% and modeling peak risk adjusted sales of $531M and $171M in respective U.S. and EU5 markets. MacKay is keeping his Outperform rating on Seattle Genetics.
10/22/19
LEER
10/22/19
NO CHANGE
Target $120
LEER
Outperform
Seattle Genetics price target raised to $120 from $102 at SVB Leerink
SVB Leerink analyst Andrew Berens raised his price target for Seattle Genetics to $120 from $102 following positive topline data from the pivotal HER2CLIMB trial for tucatinib. The analyst remains bullish on Seattle Genetics as a pipeline driven story, with positive momentum driven by enthusiasm for enfortumab vedotin in bladder cancer following strong data presented at ESMO, tucatinib HER2CLIMB success, which provides the company's first win in small molecules and a catalyst for a global footprint, and increasing confidence in the ADC + I/O synergy story, driving increased fundamental and strategic value for the ADC platform. He reiterates an Outperform rating on the shares.
10/29/19
PIPR
10/29/19
NO CHANGE
Target $120
PIPR
Overweight
Seattle Genetics price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro raised his price target on Seattle Genetics to $120 after its "modest" beat on Adcetris revenue in Q3 along with an upwardly narrowed outlook for FY19. The analyst notes that the company has an "additional opportunity" driven by the potential launch for its Enfortumab vedotin, or EV, in 3rd-line UBC in 2020, along with other opportunities across the pipeline over the near term. Catanzaro also keeps his Overweight rating on Seattle Genetics.
ALPMY Astellas Pharma
$0.00

(0.00%)

09/24/19
JEFF
09/24/19
INITIATION
JEFF
Buy
Astellas Pharma initiated with a Buy at Jefferies
Jefferies analyst Stephen Barker started Astellas Pharma with a Buy rating and 2,000 yen price target.
MRK Merck
$87.10

-0.52 (-0.59%)

10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill
10/18/19
MZHO
10/18/19
NO CHANGE
Target $97
MZHO
Buy
Merck's Keytruda pulling farther ahead of competition, says Mizuho
Mizuho analyst Mara Goldstein reiterated her Buy rating and $97 price target on Merck shares after the announcement of positive EU CHMP opinions for Keytruda monotherapy and in combination with chemotherapy for first-line head and neck squamous cell carcinoma, or HNSCC. She sees Keytruda pulling farther ahead of its competition as the leading checkpoint inhibitor as it continues to penetrate additional tumor types and global markets, Goldstein tells investors.
10/30/19
MZHO
10/30/19
NO CHANGE
Target $100
MZHO
Buy
Merck price target raised to $100 from $97 at Mizuho
Mizuho analyst Mara Goldstein raised her price target for Merck to $100 from $97 saying the company delivered a "strong" Q3 earnings beat and raised fiscal 2019 sales and EPS guidance. The analyst continues to see opportunity for Keytruda to drive a profit transformation over the next several years and reiterates a Buy rating on the shares.
11/08/19
LEER
11/08/19
NO CHANGE
LEER
Outperform
Merck data a 'much needed positive' for Aduro Biotech, says SVB Leerink
SVB Leerink analyst Daina Graybosch noted that Merck (MRK) presented data in a late-breaking oral session at the SITC meeting on the dose escalation and confirmation phases of its trial of MK-5890, which is licensed from Aduro Biotech (ADRO). The "surprisingly positive" signal in dose escalation, while very early, should not have much stock impact for Merck, but for Aduro "this is some much needed positive news," according to Graybosch. She has an Outperform rating on Aduro shares.

TODAY'S FREE FLY STORIES

TWNK

Hostess Brands

$14.14

0.21 (1.51%)

16:34
12/11/19
12/11
16:34
12/11/19
16:34
Initiation
Hostess Brands initiated  »

Hostess Brands resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLHC

DLH Holdings

$4.39

0.34 (8.40%)

16:34
12/11/19
12/11
16:34
12/11/19
16:34
Earnings
DLH Holdings reports Q4 EPS 12c, two estimates 14c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NDSN

Nordson

$167.47

1.72 (1.04%)

16:34
12/11/19
12/11
16:34
12/11/19
16:34
Earnings
Nordson reports Q4 EPS $1.79, consensus $1.79 »

Reports Q4 revenue $585M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BKH

Black Hills

$77.19

0.55 (0.72%)

16:33
12/11/19
12/11
16:33
12/11/19
16:33
Hot Stocks
Black Hills' Wyoming utility receives approval for consolidation, rate increase »

Black Hills Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$0.69

0.0554 (8.73%)

16:32
12/11/19
12/11
16:32
12/11/19
16:32
Hot Stocks
Miragen Therapeutics announces Diana Escolar CMO, $20M stock purchase agreement »

The company announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$13.68

0.05 (0.37%)

16:32
12/11/19
12/11
16:32
12/11/19
16:32
Hot Stocks
Cott Corp. board approves share repurchase of up to $50M »

Cott Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

R

Ryder

$51.38

-0.465 (-0.90%)

16:31
12/11/19
12/11
16:31
12/11/19
16:31
Hot Stocks
Ryder announces new 1.5M share repurchase program »

Ryder System announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 13

    Feb

16:30
12/11/19
12/11
16:30
12/11/19
16:30
Options
Preliminary option volume of 17.3M today »

Preliminary option volume…

FVRR

Fiverr

$21.65

0.11 (0.51%)

16:28
12/11/19
12/11
16:28
12/11/19
16:28
Initiation
Fiverr initiated  »

Fiverr initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SMPL

Simply Good Foods

$27.89

-0.2 (-0.71%)

16:27
12/11/19
12/11
16:27
12/11/19
16:27
Initiation
Simply Good Foods initiated  »

Simply Good Foods resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRS

Amyris

$3.24

-0.09 (-2.70%)

16:25
12/11/19
12/11
16:25
12/11/19
16:25
Initiation
Amyris initiated  »

Amyris initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APT

Alpha Pro Tech

$3.36

-0.015 (-0.45%)

16:24
12/11/19
12/11
16:24
12/11/19
16:24
Hot Stocks
Alpha Pro Tech adds additional $2M to share repurchase program »

Alpha Pro Tech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$0.69

0.0554 (8.73%)

16:24
12/11/19
12/11
16:24
12/11/19
16:24
Hot Stocks
Miragen Therapeutics to cut Phase 2 SOLAR enrollment, focus pipeline on MRG-229 »

Miragen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NX

Quanex

$19.76

0.715 (3.76%)

16:23
12/11/19
12/11
16:23
12/11/19
16:23
Earnings
Quanex sees FY20 revenue $865M-$885M, consensus $911.52M »

Bill Griffiths, chairman,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

PDSB

PDS Biotechnology

$2.85

0.05 (1.79%)

, MRK

Merck

$88.96

-0.12 (-0.13%)

16:23
12/11/19
12/11
16:23
12/11/19
16:23
Hot Stocks
PDS Biotechnology says Dr. Jared Weiss principal investigator in Versatile study »

PDS Biotechnology (PDSB)…

PDSB

PDS Biotechnology

$2.85

0.05 (1.79%)

MRK

Merck

$88.96

-0.12 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ZTS

Zoetis

$123.61

0.82 (0.67%)

16:22
12/11/19
12/11
16:22
12/11/19
16:22
Hot Stocks
Zoetis raises quarterly dividend 22% to 20c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVA

Covanta

$14.83

0.075 (0.51%)

16:22
12/11/19
12/11
16:22
12/11/19
16:22
Hot Stocks
Covanta to build new energy-from-waste facility in Zhao County, China »

Covanta has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$50.42

-0.02 (-0.04%)

16:21
12/11/19
12/11
16:21
12/11/19
16:21
Hot Stocks
AIG extends tax asset protection plan »

American International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AB

AllianceBernstein

$28.81

0.065 (0.23%)

16:21
12/11/19
12/11
16:21
12/11/19
16:21
Hot Stocks
AllianceBernstein reports preliminary AUM $611B as of November 30 »

Up from $601B at the end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NX

Quanex

$19.76

0.715 (3.76%)

16:21
12/11/19
12/11
16:21
12/11/19
16:21
Earnings
Quanex reports Q4 EPS 42c, consensus 38c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

UTX

United Technologies

$147.29

1.91 (1.31%)

16:20
12/11/19
12/11
16:20
12/11/19
16:20
Hot Stocks
United Technologies names board members for future independent Carrier »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSG

Overseas Shipholding

$1.80

-0.025 (-1.37%)

16:20
12/11/19
12/11
16:20
12/11/19
16:20
Hot Stocks
Overseas Shipholding, American Shipping extend tanker charters »

Overseas Shipholding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
12/11/19
12/11
16:20
12/11/19
16:20
Options
Closing CBOE SPX and VIX Index summary for December 11th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$147.29

1.91 (1.31%)

16:19
12/11/19
12/11
16:19
12/11/19
16:19
Hot Stocks
United Technologies names board members for future independent Otis »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$21.63

0.11 (0.51%)

16:19
12/11/19
12/11
16:19
12/11/19
16:19
Hot Stocks
Associated Banc-Corp Chief Credit Officer John Hankerd retiring in Q1 »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.